Alto Neuroscience (ANRO) Institutional Ownership
13F filers reported holding 73.7% of Alto Neuroscience (ANRO) shares as of Jun 30, 2026, across 116 filers.
4 figures withheld by our checks. Each blank figure names its reason.
- Held by 13F filers
- 73.7%
- Jun 30, 2026
- 13F filers
- 116
- quarter ended Jun 30, 2026
- 13F value
- $780.4M
- 29.6M shares
Is the smart money (institutions and insiders) accumulating or distributing? One lagging input, not a buy signal.
| Date | Name | Role | Type | Shares | Price** | SEC filing |
|---|---|---|---|---|---|---|
| Oct 2, 2026 | Smith Nicholas Conrad | PRESIDENT AND CFO | Acquired · Option exercise | 55,000 | $2.32 | ↗ |
| Oct 2, 2026 | Smith Nicholas Conrad | PRESIDENT AND CFO | Disposed · Option exercise | 55,000Employee Stock Option (Right to Buy) | — | ↗ |
| Sep 30, 2026 | Smith Nicholas Conrad | PRESIDENT AND CFO | Acquired · Option exercise | 24,056 | $2.35 | ↗ |
| Sep 30, 2026 | Smith Nicholas Conrad | PRESIDENT AND CFO | Disposed · Open-market sale | 23,170 | $25.78 | ↗ |
| Sep 30, 2026 | Smith Nicholas Conrad | PRESIDENT AND CFO | Disposed · Open-market sale | 886 | $26.87 | ↗ |
| Sep 30, 2026 | Smith Nicholas Conrad | PRESIDENT AND CFO | Disposed · Option exercise | 24,056Employee Stock Option (Right to Buy) | — | ↗ |
| Sep 29, 2026 | Smith Nicholas Conrad | PRESIDENT AND CFO | Acquired · Option exercise | 56,455 | $2.35 | ↗ |
| Sep 29, 2026 | Smith Nicholas Conrad | PRESIDENT AND CFO | Acquired · Option exercise | 54,375 | $2.35 | ↗ |
| Sep 29, 2026 | Smith Nicholas Conrad | PRESIDENT AND CFO | Disposed · Open-market sale | 110,830 | $26.58 | ↗ |
| Sep 29, 2026 | Smith Nicholas Conrad | PRESIDENT AND CFO | Disposed · Option exercise | 56,455Employee Stock Option (Right to Buy) | — | ↗ |
| Sep 29, 2026 | Smith Nicholas Conrad | PRESIDENT AND CFO | Disposed · Option exercise | 54,375Employee Stock Option (Right to Buy) | — | ↗ |
| May 27, 2026 | Miller Andrew Craig | director | Acquired · Grant / award | 26,000Stock Option (right to buy) | — | ↗ |
| May 14, 2026 | Etkin Amit | PRESIDENT AND CEO | Disposed · Gift | 400,000 | — | ↗ |
| May 12, 2026 | Manji Husseini | director | Acquired · Grant / award | 10,958Stock Option (right to buy) | — | ↗ |
| May 12, 2026 | York Gwill | director | Acquired · Grant / award | 10,958Stock Option (right to buy) | — | ↗ |
| May 12, 2026 | Cox Christopher Nixon | director | Acquired · Grant / award | 10,958Stock Option (right to buy) | — | ↗ |
| May 12, 2026 | Sanchez Ramiro | director | Acquired · Grant / award | 10,958Stock Option (right to buy) | — | ↗ |
| May 12, 2026 | Dreyfus Andrew | director | Acquired · Grant / award | 10,958Stock Option (right to buy) | — | ↗ |
| Mar 1, 2026 | Smith Nicholas Conrad | CHIEF FINANCIAL OFFICER & CBO | Disposed · Tax withholding | 2,806 | $19.69 | ↗ |
| Mar 1, 2026 | Etkin Amit | PRESIDENT AND CEO | Disposed · Tax withholding | 6,227 | $19.69 | ↗ |
* Holdings as reported for Jun 30, 2026, 140 days old; funds file up to 45 days after each quarter-end, so the newest complete quarter runs 45 to 135 days behind.
** A price of “—” marks an option exercise, RSU vest or a filing without a usable per-share price, not a $0 trade.
Common questions
How much of Alto Neuroscience do institutions hold?
13F filers reported holding 73.7% of Alto Neuroscience's shares as of Jun 30, 2026, across 116 filers.
How many 13F filers hold Alto Neuroscience?
Alto Neuroscience was held by 116 13F filers as of Jun 30, 2026.
Not investment advice.

